Lehman Jonathan M, Gwin Mary E, Massion Pierre P
Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN, 37232, USA.
Vanderbilt University, PMB 353746, 2301 Vanderbilt Place, Nashville, TN, 37235, USA.
Curr Oncol Rep. 2017 Jul;19(7):49. doi: 10.1007/s11912-017-0609-2.
Small cell lung cancer (SCLC) is a devastating and aggressive neuroendocrine carcinoma of the lung. It accounts for ~15% of lung cancer mortality and has had no improvement in standard treatment options for nearly 30 years. However, there is now hope for change with new therapies and modalities of therapy. Immunotherapies and checkpoint inhibitors are entering clinical practice, selected targeted therapies show promise, and "smart bomb"-based drug/radioconjugates have led to good response in early clinical trials. Additionally, new research insights into the genetics and tumor heterogeneity of SCLC alongside the availability of new tools such as patient-derived or circulating tumor cell xenografts offer the potential to shine light on this beshadowed cancer.
小细胞肺癌（SCLC）是一种具有侵袭性的毁灭性肺神经内分泌癌。它占肺癌死亡率的约15%，近30年来标准治疗方案一直没有改进。然而，随着新疗法和治疗方式的出现，现在有了改变的希望。免疫疗法和检查点抑制剂正在进入临床实践，某些靶向疗法显示出前景，基于“智能炸弹”的药物/放射性缀合物在早期临床试验中已产生良好反应。此外，对SCLC的遗传学和肿瘤异质性的新研究见解，以及诸如患者来源或循环肿瘤细胞异种移植等新工具的可用性，为揭示这种隐匿性癌症提供了可能。
